NCT06341556View on ClinicalTrials.gov

A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2028

Conditions
Mantle Cell LymphomaMaintenance Therapy
Interventions
DRUG

Zanubrutinib

Patients diagnosed with mantle cell lymphoma who have achieved remission (CR or PR) by first-line immunochemotherapy, will be treated with Zanubrutinib monotherapy for 2 years (or until PD, intolerable toxicity, death, withdrawal, or study termination).

Trial Locations (2)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

RECRUITING

Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER